Merck, a leading science and technology company, has entered into a non-binding Memorandum of Understanding (MoU) with Gene Therapy Research Institution Co., Ltd. (GTRI), a Japanese biotech start-up focused on gene therapy using adeno-associated virus (AAV) vectors. Under this MoU, GTRI will leverage Merck’s Sf-RVN® Insect Cell Line platform for the GMP production of its viral vector-based gene therapy targeting Parkinson’s Disease.
“In Japan, we are seeing promising clinical trials for gene therapy medicines aimed at developing new treatments for various diseases,” said Isao Hatano, Head of Process Solutions, Japan, Life Science business at Merck. “Our extensive range of products and services will support GTRI in accelerating the development and manufacturing of viral vector-based therapies. We are optimistic that this partnership will contribute to providing effective treatments for patients with severe conditions.”
Through the MoU, Merck and GTRI will collaborate to establish a robust AAV production platform for scaling up production. This partnership will involve utilizing Merck’s cell line and platform technologies for developing viral vector-based therapies.
Moreover, Merck will offer GTRI technical support, training, and process optimization at the M Lab™ Collaboration Center in Tokyo.
“Our mission since 2014 has been to develop innovative gene therapy techniques for challenging diseases with limited treatment options, primarily focusing on Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS),” said Katsuhito Asai, CEO of GTRI. “One of our major challenges is creating robust and safe manufacturing processes for viral vectors used in gene therapy, which is significantly more complex than producing traditional antibody drugs. This partnership with Merck will streamline the production process and expedite the availability of these therapies.”
Earlier this year, Merck also announced a collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support research aimed at slowing the progression of Parkinson’s disease.
